How lucky we are in NZ with our smoke-free legislation! This became apparent after we presented our local data on the effect of the Christchurch earthquake on smoking prevalence at an international conference. After the session, the chairperson reported that her town in southern Turkey had also suffered an earthquake. Winchester was quick to respond by driving trucks with free cigarettes to 'aid' the suffering people. This 'brand switching' exercise was very successful. When our colleague enquired why the local health authorities had permitted this advertising campaign, she was punished with disciplinary measures for shedding a bad light on health authorities. NZ has the ambitious aim to be the first country in the world to be virtually smoke free by 2025. It is likely that it will suffer international pressure, similar to that seen for the 'nuclear-free' campaign in the 1980s. Examples of such pressure can be read in the Lancet (Lancet 2012;380[9852]:1447-8), which reads more like a script for an action movie -pressure on the headquarters of the European Respiratory Society include 'dark unmarked cars' parked outside staff members' homes, people abseiling from the roof to break into offices and tales of stolen identities. It is with these events in mind that we are reviewing, in the year of the 100 th birthday of Sir Richard Doll (Am J Respir Crit Care Med 2012;186[11]), the Million Woman study, providing beautifully written, clearly presented evidence on the damage of smoking and the benefits of smoking cessation. There may well be a time when any one of us needs to back up our local representatives with solid data and not waver under the pressure the Transpacific Trade Agreement may create (www.itsourfuture.org.nz). We are also taking a more critical look at the treatment regimens available for the management of COPD. Comment: Published on the 100th birthday of Sir Richard Doll, the Lancet published the Million woman study and the accompanying editorial by Rachel Huxley and Mark Woodward (Lancet http://dx.doi.org/10.1016/S0140-6736(12)61780-2), who summarised the results: i) the mortality of smokers is triple that to never-smokers; ii) 'social smokers' mortality is close to double to that of never-smokers; iii) smoking throughout adulthood reduced life expectancy by about 11 years; iv) women who stop smoking before the age of 30 years avoided nearly 100% of the excess mortality, and stopping before age 40 years avoided 90% of the excess mortality. Bottom line, after Sir Richard Doll: ways must be found to limit the vast damage being done by tobacco. This study examined the association between second-hand smoke and mortality from ischaemic stroke and COPD in China. The cohort comprised 910 participants of a 17-year follow-up study. Second-hand smoke exposure was defined as exposure to another person's tobacco smoke at home or in the workplace; 249 men and women died during follow-up. People who were exposed to second-hand smoke had increased all-cause mortality (adjusted relative risk 1.72 [95% CI 1.29, 2.20]), and increased mortality due to COPD (2.30 [1.06, 5.50]), coronary heart disease (2.15 [1.00, 4.61]), ischaemic stroke (2.88 [1.10, 7.55]) and lung cancer (2.00 [0.62, 6.40]).The association between cumulative secondhand smoke exposure at home and work and the increased risk of mortality was dose-dependent.
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Comment: Unfortunately China is a good place to study the effects of second-hand smoke, with 67% of the male and 4% of the female population smoking. China is also the largest producer and consumer of tobacco in the world. This is the first time that a study has prospectively shown conclusively an increase in ischaemic stroke (188%) and COPD (130%) in people who have never smoked but were exposed to second-hand smoke at their work place, home or both. Bottom line: second-hand smoke shows a dose response relationship to ischaemic stroke and COPD in neversmokers.
Reference: Chest 2012;142(4):909-18
http://journal.publications.chestnet.org/article.aspx?articleid=1216045
Weight gain in smokers after quitting cigarettes Authors: Aubin H-J et al
Summary:
This meta-analysis included 62 published studies of bodyweight gain among smokers who had achieved prolonged abstinence for ≤12 months and who quit without treatment or use of drugs to assist cessation. The analyses revealed that smoking cessation was associated with a mean increase of 4-5kg in bodyweight after 12 months of abstinence, with substantial differences among study participants. Most of the postcessation weight gain occurred during the first 3 months.
Comment: One of the most common and long-lasting symptoms of tobacco withdrawal is increased appetite. Furthermore, nicotine increases the basal metabolic rate, an effect reversed on smoking cessation. Adolescents who initiate smoking gain less weight than their nonsmoking peers. It is well documented and not surprising that people who stop smoking will gain weight. This very thorough meta-analysis from researchers at a French addiction centre and UK Centre of Tobacco control came up with a clear bottom line: "smoking cessation is associated with a mean increase in body weight of about 4-5kg after 1 year, with most weight gain occurring within three months of quitting". Reference: BMJ 2012; 345:e4439 http://www.bmj.com/content/345/bmj.e4439
Respiratory Research Review
Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease Authors: Divo M et al, for the BODE Collaborative Group Summary: These researchers systematically recorded 79 comorbidities in 1664 patients with COPD who were followed for a median of 51 months. Of these comorbidities, the prevalence of 15 differed between survivors and nonsurvivors, and of those, 12 predicted mortality and were integrated into a COPD mortality index 'COTE'. COTE index increases were associated with an increased mortality risk from both COPD-and non-COPD-related causes (respective HRs 1.13 [95% CI 1.08, 1.18; p<0.001] and 1.18 [1.15, 1.21; p<0.001]). Furthermore, both BODE and COTE index score increases were independently associated with increased mortality risk. A COTE index score ≥4 points was associated with a significantly increased mortality risk across all BODE quartiles (HRs 2.26-2.68; p values <0.001).
Comment: The senior author is Bart Celli of the BODE index, which has made it into text books. It utilises Body mass index, airway Obstruction FEV 1 , Dyspnoea and Exercise capacity to determine the risk of death in COPD. Because it doesn't take into account comorbidities, the authors used data from the ongoing BODE cohort to give us the COTE index: COmorbidity TEst. They presented a 'comorbidome', in which the authors summarised prevalence and mortality in one diagram. Bottom line: anxiety, cancer, pulmonary fibrosis, liver cirrhosis, ulcers, diabetes, atrial flutter, CHF and coronary heart disease are associated with an increased risk of death. This study evaluated the prevalence and implications of coexisting LV dysfunction in patients with COPD, and concurrent airway obstruction in patients with CHF. Patients with CHF (n=201) underwent routine spirometry, and patients with COPD (218) underwent routine echocardiographic assessment and B-type natriuretic peptide measurements before being followed for 2 years. Coexisting airway obstruction was present in 37.3% of patients with CHF, and 17% of patients with COPD had coexisting LV dysfunction. Airway obstruction in CHF patients had no impact on survival during follow-up, but the presence of ventricular dysfunction in patients with COPD slightly increased the risk of mortality (HR 2.34 [95% CI 0.99, 5.54; p=0.053]).
Comment: These Argentinean authors presented data from their prospective REPENSAR ('re-think') cohort on patients presenting with either COPD or heart failure. The authors systematically investigated participants for evidence of airflow obstruction and ventricular dysfunction. They found that 37% of patients presenting with heart failure also had COPD; 17% of patients presenting with COPD also had LV dysfunction on echocardiography. Most treating physicians were not aware of the co-existing morbidities. The presence of ventricular dysfunction increased the probability of dying 2.34-fold. Bottom line: these findings make us rethink and possibly reinvestigate the safety and efficacy of pharmacological agents in 'real-life' populations. Comment: This is the first of two articles investigating the risk for cardiac arrhythmias associated with use of ipratropium bromide, long-acting β-agonists, short-acting β-agonists and methylxanthines. The authors used Saskatchewan data with endpoints of an arrhythmic death or hospital admission with arrhythmia. Like all retrospective studies it has many weaknesses, not the least that no spirometry or smoking data were available, and it needs to be interpreted with caution also because of its relatively small numbers. Concerns are raised by the authors' bottom line: short-acting anticholinergic agents and possibly long-acting β-agonists increase the risk of cardiac arrhythmias. 
Reference: Eur

Comment:
The same Canadian authors used data from 76,000 patients with COPD to investigate the pro-arrhythmogenic effect of our standard therapies in COPD. This time the authors could not identify an adverse outcome after the use of anticholinergic medications; however, they raised concerns about excess cardiac arrhythmias following the new use of short-and long-acting β-agonists. Our current president of the European Respiratory Society, Klaus Rabe, has summarised the implication in a thoughtful accompanying editorial (Chest 2012; 142[2] :271-4) and has given us our bottom line: Comment: This study comes from Newcastle upon Tyne, where I completed my training in respiratory medicine. The authors reflected on the fact that the BODE index predicts mortality risk in stable COPD patients; however, no simple score estimates the mortality in patients admitted with an acute exacerbation of COPD. After recruiting 920 patients with an acute exacerbation of COPD in two hospitals over an 18-month period, they found that about 10% died during admission. Furthermore, they found that the five strongest predictors of mortality were Dyspnoea, Eosinopenia, Consolidation, Acidaemia and atrial Fibrillation (DECAF). Bottom line: this simple clinical prediction tool can accurately stratify patients who are admitted with an acute exacerbation of COPD.
Reference: Thorax 2012; 67(11):970-6 http://thorax.bmj.com/content/67/11/970
The calcium sensitizer levosimendan improves human diaphragm function
Authors: Doorduin J et al Summary: These researchers got 30 healthy subjects to perform two identical inspiratory loading tasks after which they received the calcium sensitiser levosimendan 40 μg/kg bolus followed by 0.1/0.2 μg/kg/min continuous infusion or placebo in a crossover design. Loss of twitch contractility during postload breathing was not seen after levosimendan, compared with a 9% loss after placebo. Furthermore, levosimendan administration was associated with a significant 21% improvement in neuromechanical efficiency of the diaphragm during loading and a significant reduction in baseline centre frequency of diaphragm electrical activity (p<0.05 for both).
Comment: This Canadian/Dutch double-blind, placebo-controlled crossover study on 30 healthy volunteers may keep alive some hope of effective therapies in the management of COPD. Working on the premise that muscle weakness is a common phenomenon and is also associated with poorer survival in COPD, they reported on a study of the effects of a calcium sensitiser on diaphragmatic muscle strength. They demonstrated that the calcium sensitiser levosimendan improved both contractile function and neuromechanical efficiency of the human diaphragm. 
